Day: March 6, 2023

AUSTIN, Texas, March 06, 2023 (GLOBE NEWSWIRE) — Volcon Inc. (NASDAQ: VLCN) (“Volcon” or the “Company”), the first all-electric, off-road powersports company, today reported its operational highlights and financial results for fiscal year 2022. Company Highlights:Through December 31, 2022 signed 151 dealers Delivered the first 2023 Volcon Brats to customers in December 2022 Have taken pre-orders for the Stag of more than $116 million if all orders are fulfilled1 Taken delivery of our first three Stag validation units in early 2023 that include our custom suspension parts in addition to the GM propulsion components Grunt EVO and Runt launch expected in the second quarter of 2023We signed 7 new dealers in the fourth quarter of 2022. Jordan Davis, CEO notes “In the fourth quarter of 2022, we purposely slowed signing of...

Company preparing to initiate Phase 3 clinical trials of TTP399, an adjunctive therapy to insulin, for the treatment of Type 1 diabetes Biotech industry and Wall Street veteran Steven Tuch appointed Executive Vice President and Chief Financial Officer Biotech industry veteran Elizabeth Keiley appointed Executive Vice President and General CounselHIGH POINT, N.C., March 06, 2023 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of Type 1 diabetes, today reported financial results for the fourth quarter and year ended December 31, 2022, and provided an update on recent corporate developments. “We have made a great deal of progress since I joined vTv early in the second half of 2022,” said Paul Sekhri,...

NEW YORK, March 06, 2023 (GLOBE NEWSWIRE) — Cellectis S.A. (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company for which Cellectis owns 49.1% (as of December 31, 2022) of its issued and outstanding common stock, today announced operating and financial results for its fourth quarter ended December 31, 2022. The contents of Calyxt’s announcement are included below: —Announced proposed merger with Cibus Global and filed initial registration statement on Form S-4— —Current customer projects under development are on track— —Signed agreement with Evologic Technologies to further develop and scale production of its Plant Cell...

First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib (DAY101) as a frontline therapy for patients newly diagnosed with pediatric low-grade glioma (pLGG) Reported topline data in January 2023 from ongoing, pivotal Phase 2 FIREFLY-1 trial demonstrating meaningful responses with tovorafenib (DAY101) in relapsed or progressive pLGG Additional data from FIREFLY-1 planned for presentation at a medical meeting in second quarter of 2023 New Drug Application (NDA) submission planned for tovorafenib (DAY101) in first half of 2023 BRISBANE, Calif., March 06, 2023 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its fourth...

HOUSTON, March 06, 2023 (GLOBE NEWSWIRE) — SEACOR Marine Holdings Inc. (NYSE: SMHI) (the “Company” or “SEACOR Marine”), a leading provider of marine and support transportation services to offshore energy facilities worldwide, today announced results for its fourth quarter ended December 31, 2022. SEACOR Marine’s consolidated operating revenues for the fourth quarter of 2022 were $57.9 million, operating loss was $10.5 million, and direct vessel profit (“DVP”)(1) was $13.6 million. This compares to consolidated operating revenues of $48.0 million, operating loss of $14.7 million, and DVP of $12.9 million in the fourth quarter of 2021, and consolidated operating revenues of $59.8 million, operating loss of $10.9 million, and DVP of $15.8 million in the third quarter of 2022. Notable fourth quarter items include:Extended the maturity...

Fourth Quarter ResultsTotal revenues of $40.2 million, an 11% year-over-year increase Net income of $2.0 million, compared to $1.7 million for the fourth quarter of 2021, a $0.3 million improvement resulting in earnings per diluted share of $0.81 Adjusted EBITDA of $6.4 million, slightly below the fourth quarter of 2021 $16.2 million in cash and $7.9 million of total debt as of December 31, 2022Full Year ResultsTotal revenues of $155.6 million, a 31% increase over the prior year Net loss of $(1.1) million, compared to a net loss of $(4.7) million in 2021, a $3.6 million improvement resulting in loss per diluted share of $(0.45) Adjusted EBITDA of $15.1 million, compared to $9.1 million in 2021, a $6.0 million improvementHOUSTON, March 06, 2023 (GLOBE NEWSWIRE) — NCS Multistage Holdings, Inc. (Nasdaq: NCSM) (the “Company,”...

– Fourth Quarter Revenues and Share of NPI Revenues Interest total $83.2 million, up 291% year-over-year – – Full Year Revenues and Share of NPI Revenues Interest was $210.2 million – – Initiates Full Year 2023 Revenue and Share of NPI Revenues Guidance representing 10.4% year-over-year growth at the midpoint on a like-for-like basis – LUXEMBOURG, March 06, 2023 (GLOBE NEWSWIRE) — NeoGames S.A. (Nasdaq: NGMS) (“NeoGames” or the “Company”), a technology-driven provider of end-to-end iLottery and iGaming solutions, announced today financial results for the fourth quarter and year ended December 31, 2022. Moti Malul, Chief Executive Officer of NeoGames, said: “We are proud of the tremendous progress we made during 2022, further solidifying our iLottery leadership position in a continually expanding market. A record year...